Nobuhiro Kubo - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Nobuhiro Kubo

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Molecular Medicine Reports|July 11, 2025

Chimeric PD‑1 receptor redirects primary T cells against childhood solid tumors but not to PD‑1 ligand‑positive CD80‑coexpressing cellsChansu Shin, Masaru Imamura, Yasushi Kasahara, et al.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 8, 2026

NKG2D-based CAR-T cells for synovial sarcoma: A preclinical proof-of-concept studyTomohiro Miyazaki, Yudai Murayama, Naoki Oike, et al.

Translational Oncology|August 23, 2022

NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcomaYudai Murayama, Yasushi Kasahara, Nobuhiro Kubo, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Molecular Medicine Reports|July 11, 2025

Chimeric PD‑1 receptor redirects primary T cells against childhood solid tumors but not to PD‑1 ligand‑positive CD80‑coexpressing cellsChansu Shin, Masaru Imamura, Yasushi Kasahara, et al.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 8, 2026

NKG2D-based CAR-T cells for synovial sarcoma: A preclinical proof-of-concept studyTomohiro Miyazaki, Yudai Murayama, Naoki Oike, et al.

Translational Oncology|August 23, 2022

NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcomaYudai Murayama, Yasushi Kasahara, Nobuhiro Kubo, et al.

Pageof 2